Metabolic Data Observed

Metabolic change data: Long-term maintenance trial1
A chart illustrating the metabolic INVEGA TRINZA® tolerability observed in patients during a clinical study
*During the open-label phase, patients received several doses of INVEGA SUSTENNA® (paliperidone palmitate) followed by a single dose of INVEGA TRINZA®.

WEIGHT GAIN:Weight gain has been reported with atypical antipsychotic use. Clinical monitoring of weight is recommended.1

Fasting glucose1
A chart illustrating the impact that INVEGA TRINZA® had on fasting glucose observed in patients during a clinical study

*During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.

Hyperglycemia and diabetes mellitus1

  • Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness
  • Monitor glucose regularly in patients with diabetes or at risk for diabetes
Fasting lipids1
A chart illustrating the impact that INVEGA TRINZA® had on fasting lipids observed in patients during a clinical study
A chart illustrating the impact that INVEGA TRINZA® had on fasting lipids observed in patients during a clinical study
A chart illustrating the impact that INVEGA TRINZA® had on fasting lipids observed in patients during a clinical study

*Values for the open-label phase and the double-blind phase are relative to their respective baselines.

During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.

DYSLIPIDEMIA:Undesirable alterations in lipids have been observed in patients treated with antipsychotics.1

Please see additional Important Safety Information below.

Reference: 1. INVEGA TRINZA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; February 2017.